Sonntag, 13. Juni 2021
Navigation öffnen
JOURNAL ONKOLOGIE – STUDIE

A Study on the Immune-response to COVID-19 Vaccination in Cancer Patients - the IOSI-COVID-19-001 Study

Rekrutierend

NCT-Nummer:
NCT04800146

Studienbeginn:
Februar 2021

Letztes Update:
16.03.2021

Wirkstoff:
-

Geschlecht:
Alle

Altersgruppe:
Alle

Phase:
-

Sponsor:
Ilaria Colombo

Collaborator:
Institute for Research in Biomedicine, Ente Ospedaliero Cantonale, Bellinzona,

Studienlocations
(1 von 1)

Studien-Informationen

Detailed Description:

This study will be conducted on 7 cohorts of cancer patients and 1 cohort of non-cancer

subjects (age and gender matched) with a sample size of 30 patients in each cohort:

All enrolled patients will be asked to provide blood samples (2 x 10cc Heparin Tubes) at the

following time points:

- Baseline: before the administration of the first dose of the SARS-CoV-2 vaccine (within

4 weeks).

- Before the second dose of the SARS-CoV-2 vaccine (within 7 days).

- Follow-up: after 3, 6, 9 and 12 months after the second dose of the SARS-CoV-2 vaccine.

A +/- 14 days window is allowed at each follow-up time point.

Ein-/Ausschlusskriterien

Inclusion Criteria:

- Male of Female age at least 18 years

- Patients with a diagnosis of malignancy (solid tumors or hematological malignancies)

according to the defined cohorts. Only for cohorts 1-7

- Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2

- Absence of known immune deficiency (other than cancer for cohorts 1-7)

- Ability to understand the patient information and study consent. Signed and dated

written informed consent must be available before performing any study-related

procedure

- Willing and able to comply with the study procedures.

- Willing to receive an mRNA anti-SARS-CoV-2 vaccine.

Studien-Rationale

Primary outcome:

1. Immune response to SARS-CoV-2 vaccine in cancer patients (Time Frame - 3, 6, 9 and 12 months following vaccination):
to determine the changes in the titer of serum antibodies (IgM, IgG and IgA) targeting SARS-CoV-2 antigens in 7 cohorts of cancer patients who have received the SARS-CoV-2 vaccination. A cohort of non-cancer subjects will be used as control group.



Secondary outcome:

1. changes in serum antibodies anti SARS-CoV-2 after vaccination (Time Frame - 3, 6, 9 and 12 months following vaccination):
To explore the dynamic changes overtime of the levels of antibodies against SARS-CoV-2 following vaccination in cancer patients and controls

2. Cellular immune response to SARS-CoV-2 vaccine (Time Frame - 3, 6, 9 and 12 months following vaccination):
To explore the dynamic changes overtime of the T cells immune response following SARS-CoV-2 vaccination in cancer patients and controls.

3. Cellular immune response to SARS-CoV-2 vaccine (Time Frame - 3, 6, 9 and 12 months following vaccination):
To explore the dynamic changes overtime of the B cells immune response following SARS-CoV-2 vaccination in cancer patients and controls.

4. Immune response to SARS-CoV-2 vaccine according tumor and treatment type (Time Frame - 3, 6, 9 and 12 months following vaccination):
To explore the correlation between the immune response against SARS-CoV-2 vaccination and the type of cancer (e.g., solid tumors versus hematological malignancies) and the type of anticancer treatment (e.g., anti-CD20, chemotherapy, targeted agents, immunotherapy, allogenic or autologous transplant)

Studien-Arme

  • Cohort 1
    patients with solid tumors treated with chemotherapy (ongoing or completed no more than 6 months before enrollment). Specific type of chemotherapy inducing similar immunosuppression will be selected (including but not limited to platinum-based combinations, anthracycline combinations, triweekly docetaxel).
  • Cohort 2
    patients with solid tumors treated with single agent immune-check points inhibitors (ongoing or completed no more than 6 months before the enrollment
  • Cohort 3
    patients with solid tumors treated with hormonal agents (ongoing or completed no more than 6 months before enrollment): any anti-androgen for prostate cancer and any anti-estrogen for breast cancer patients.
  • Cohort 4
    patients with previously untreated mature B cell tumors in watch and wait
  • Cohort 5
    patients with mature B cell tumors treated with anti-CD20 monoclonal antibody either alone or in combination with chemotherapy (ongoing or completed no more than 12 months before enrollment
  • Cohort 6
    patients with hematological malignancies treated with pathway inhibitors (ongoing or completed no more than 12 months before enrollment). Different type of targeted agents can be considered, including Bruton tyrosine kinase (BTK) inhibitors, B-cell lymphoma 2 (BCL-2) inhibitors or phosphoinositide-3 kinase (PI3K) inhibitors
  • Cohort 7
    patients with hematological malignancies who have received autologous stem cell or allogenic transplant within 12 months
  • Cohort 8
    non-cancer subjects (age and gender matched) referred to the Division of Infectious Diseases, Lugano, EOC for vaccination against SARS-CoV-2.

Geprüfte Regime

  • Blood sample:
    Patients will be asked to provide blood samples at specified time points: before and after the SARS-CoV-2 vaccination

Quelle: ClinicalTrials.gov


Das könnte Sie auch interessieren
Wirksamkeitsstudie wird mit 1,5 Millionen Euro gefördert
Wirksamkeitsstudie+wird+mit+1%2C5+Millionen+Euro+gef%C3%B6rdert
©Photographee.eu - stock.adobe.com

Ein Forschungsteam der Medizinischen Fakultät der Universität Duisburg-Essen (UDE) untersucht in einer Studie, wie effektiv Menschen mit einer Krebserkrankung durch das Online-Tool Make It (1)  geholfen werden kann. Das Bundesministerium für Bildung und Forschung (BMBF) unterstützt die Arbeit des Teams der Klinik für Psychosomatische Medizin und Psychotherapie am LVR-Klinikum Essen mit rund 1,5 Millionen Euro bis...